Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ICAM-1/CD54 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ICAM-1 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ICAM1 Products |
| Gene Delivery | ICAM-1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for native conformation cell-based assays. |
View ICAM1 Products |
| Benchmark Ab | Anti-ICAM-1 Recombinant Antibody (Sequence of BI-505) Recombinant positive control for binding and functional assays. |
View ICAM1 Products |
| Validator | ICAM-1 siRNA Set For target knockdown verification and specificity controls. |
View ICAM1 Products |
| Related Target A | ITGAL (LFA-1 Alpha) Primary physiological ligand for ICAM-1; critical for adhesion and immune synapse assays. |
View ITGAL Products |
| Related Target B | ITGB2 (LFA-1 Beta) Dimerizes with ITGAL; required to reconstitute functional LFA-1 receptor complexes. |
View ITGB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Soluble ICAM-1 (sICAM-1) Decoy Interference | High-purity recombinant human ICAM-1 ECD-Fc proteins for competitive binding and SPR kinetics analysis. |
| Cross-Species Reactivity Evaluation | Sequence-verified Human, Cynomolgus, and Mouse ICAM-1 ortholog proteins available with >95% purity. |
| Cell-based Adhesion & Killing Assays | High-titer Lentivirus particles for stable ICAM-1 expression to bypass artificial VLP limitations. |
| Off-target Toxicity Risk (Affinity Tuning) | Purified ECD-Fc proteins with native HEK293 glycosylation to support precise KD determination. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ICAM-1/CD54 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ICAM-1/CD54 therapeutics is intensifying, with major players shifting focus from traditional naked mAbs to CAR-T therapies, antibody-drug conjugates (ADCs), and bispecific constructs. ICAM-1 (Intercellular Adhesion Molecule 1) is heavily upregulated in triple-negative breast cancer (TNBC), multiple myeloma, and anaplastic thyroid cancer, making it a highly attractive tumor-associated antigen. As first-generation therapies reach the clinic, the next wave of R&D is targeting affinity-tuned binders to maximize tumor selectivity while sparing healthy tissues expressing low levels of baseline ICAM-1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T | AffyImmune Therapeutics (AIC100) | Anaplastic Thyroid Cancer, Poorly Differentiated Thyroid Cancer | Cell-based cytotoxicity assays (Need Lentivirus for stable target cell lines) |
| ADC | Academic / Biotech Consortia | Solid Tumors, TNBC | Internalization Assay (Need high-purity ECD-Fc for conjugation and tracking) |
| Monoclonal Antibody | BioInvent (BI-505) | Multiple Myeloma, Hematological Malignancies | Fc-mediated effector function assays (Need sequence-verified benchmark mAb) |